HomeRLF • SWX
add
RELIEF THERAPEUTICS Holding SA
Previous close
CHF 2.36
Day range
CHF 2.31 - CHF 2.49
Year range
CHF 1.06 - CHF 7.60
Market cap
34.89M CHF
Avg Volume
26.15K
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Market news
Financials
Income Statement
Revenue
Net income
| (CHF) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 1.38M | -8.21% |
Operating expense | 2.63M | -48.44% |
Net income | -6.28M | 69.86% |
Net profit margin | -454.65 | 67.17% |
Earnings per share | — | — |
EBITDA | -1.45M | 58.14% |
Effective tax rate | 18.21% | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 15.08M | 3.54% |
Total assets | 53.22M | -30.33% |
Total liabilities | 16.56M | -31.46% |
Total equity | 36.66M | — |
Shares outstanding | 12.54M | — |
Price to book | 0.81 | — |
Return on assets | -7.07% | — |
Return on capital | -9.70% | — |
Cash Flow
Net change in cash
| (CHF) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -6.28M | 69.86% |
Cash from operations | 125.00K | 103.50% |
Cash from investing | 2.20M | -50.56% |
Cash from financing | -123.00K | -98.39% |
Net change in cash | 2.18M | 146.71% |
Free cash flow | 1.25M | -47.41% |
About
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG and listed on the SIX Swiss Exchange in 2016. Wikipedia
Founded
2013
Website
Employees
31
